JP2024521696A5 - - Google Patents
Info
- Publication number
- JP2024521696A5 JP2024521696A5 JP2023571764A JP2023571764A JP2024521696A5 JP 2024521696 A5 JP2024521696 A5 JP 2024521696A5 JP 2023571764 A JP2023571764 A JP 2023571764A JP 2023571764 A JP2023571764 A JP 2023571764A JP 2024521696 A5 JP2024521696 A5 JP 2024521696A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- subject
- seq
- administered
- bispecific anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190004P | 2021-05-18 | 2021-05-18 | |
| US63/190,004 | 2021-05-18 | ||
| PCT/IB2022/054628 WO2022243900A1 (en) | 2021-05-18 | 2022-05-18 | Methods for identifying cancer patients for combination treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521696A JP2024521696A (ja) | 2024-06-04 |
| JP2024521696A5 true JP2024521696A5 (https=) | 2025-05-19 |
Family
ID=81927585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571764A Withdrawn JP2024521696A (ja) | 2021-05-18 | 2022-05-18 | 併用治療のためのがん患者を同定するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220372581A1 (https=) |
| EP (1) | EP4341440A1 (https=) |
| JP (1) | JP2024521696A (https=) |
| KR (1) | KR20240007758A (https=) |
| CN (1) | CN117716050A (https=) |
| AU (1) | AU2022276181A1 (https=) |
| BR (1) | BR112023024079A2 (https=) |
| CA (1) | CA3220465A1 (https=) |
| MX (1) | MX2023013784A (https=) |
| TW (1) | TW202309094A (https=) |
| WO (1) | WO2022243900A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| CN120131659B (zh) * | 2025-05-09 | 2025-10-28 | 中国医学科学院基础医学研究所 | Mobocertinib与抗PD-1抗体联合应用治疗癌症的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| MX2013002084A (es) * | 2010-08-31 | 2013-05-09 | Genentech Inc | Biomarcadores y metodos de tratamiento. |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| MX361088B (es) | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| EP2929350A4 (en) * | 2012-12-04 | 2016-11-16 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
| JP2016515380A (ja) * | 2013-03-15 | 2016-05-30 | ライフ テクノロジーズ コーポレーション | 肺癌の分類及び実施可能性インデックス |
| US20200157563A1 (en) * | 2017-07-18 | 2020-05-21 | The Broad Institute, Inc. | Methods of producing human cancer cell models and methods of use |
-
2022
- 2022-05-17 TW TW111118423A patent/TW202309094A/zh unknown
- 2022-05-18 WO PCT/IB2022/054628 patent/WO2022243900A1/en not_active Ceased
- 2022-05-18 BR BR112023024079A patent/BR112023024079A2/pt unknown
- 2022-05-18 US US17/747,346 patent/US20220372581A1/en not_active Abandoned
- 2022-05-18 JP JP2023571764A patent/JP2024521696A/ja not_active Withdrawn
- 2022-05-18 CN CN202280050684.9A patent/CN117716050A/zh active Pending
- 2022-05-18 AU AU2022276181A patent/AU2022276181A1/en active Pending
- 2022-05-18 EP EP22727440.4A patent/EP4341440A1/en not_active Withdrawn
- 2022-05-18 MX MX2023013784A patent/MX2023013784A/es unknown
- 2022-05-18 CA CA3220465A patent/CA3220465A1/en active Pending
- 2022-05-18 KR KR1020237043058A patent/KR20240007758A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dziadziuszko et al. | Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP) | |
| Tan et al. | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer | |
| CN110678483B (zh) | 用抗pd-1抗体治疗肿瘤的方法 | |
| CN111032082B (zh) | Her2阳性癌症的治疗 | |
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| JP2022521610A5 (https=) | ||
| CN110325191A (zh) | 以较少的副作用治疗egfr-驱动的癌症 | |
| US11845994B2 (en) | Response to EGFR blockade | |
| US8426418B2 (en) | Method to treat melanoma in BRAF inhibitor-resistant subjects | |
| TW201032796A (en) | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor | |
| CN112912403A (zh) | 治疗肿瘤的方法 | |
| McPherson et al. | A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma | |
| JP2024521696A5 (https=) | ||
| US20190269666A1 (en) | Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer | |
| CN103717616A (zh) | 表皮生长因子受体基因中的突变 | |
| Kim et al. | Pembrolizumab plus mFOLFOX7 or FOLFIRI for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 cohorts B and D | |
| Spicer et al. | A phase II study of neoadjuvant opnurasib KRAS G12C inhibitor in patients with surgically resectable non-small cell lung cancer (CCTG IND. 242A): A substudy of the IND. 242 platform master protocol | |
| CN107949401A (zh) | 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物 | |
| Kim et al. | An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations | |
| WO2023159066A1 (en) | Use of niraparib for the treatment of brain cancer | |
| CN117561062A (zh) | 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法 | |
| TW202320790A (zh) | 治療癌症之方法 | |
| RU2023132992A (ru) | Способы выявления пациентов с онкологическими заболеваниями для комбинированного лечения | |
| JP2023523450A5 (https=) | ||
| US20260116962A1 (en) | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer |